Pyrazole compounds and method for making and using the compounds

Patent metadata

Field	Value
Publication number	US-10208074-B2
Application number	US-201815928335-A
Country	US
Kind code	B2
Filing date	Mar 22, 2018
Priority date	Apr 22, 2015
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

First claim

We claim:

1. A compound having a formula

or a pharmaceutically acceptable salt thereof, wherein:
R 2 is alkyl or cycloalkyl;
each of R 4 , R 5 , R 6 , and R 7 independently is H or F;
R 8 and R 9 are each independently H or aliphatic;
R 10 is H, aliphatic, carboxyl ester, acyl, alkyl phosphate, alkyl phosphonate or aralkyl; and
R 14 is H or aliphatic.

2. The compound of claim 1 , wherein R 8 and R 9 are each independently H, haloalkyl, or alkyl.

3. The compound of claim 1 , wherein R 10 is H, alkyl, carboxyl ester, acyl, alkyl phosphate, alkyl phosphonate or aralkyl.

4. The compound of claim 1 , wherein:
R 8 and R 9 are each independently H, haloalkyl, or alkyl; and
R 10 is H, alkyl, alkyl phosphate, or alkyl phosphate.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. A composition, comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

9. The composition of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The composition of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The composition of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Rigel Pharmaceuticals Inc

Inventors

• Kelley Ryan
• Li Hui
• Heckrodt Thilo
• Chen Yan
• Mcmurtrie Darren
• Tso Kin
• Taylor Vanessa
• Singh Rajinder
• Yen Rose
• Maung Jack

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/02

  Antidotes · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title